Description: Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Home Page: www.codiakbio.com
CDAK Technical Analysis
35 Cambridge Park Drive
Cambridge,
MA
02140
United States
Phone:
617 949 4100
Officers
| Name | Title |
|---|---|
| Dr. Douglas Edward Williams Ph.D. | Pres, CEO & Director |
| Ms. Linda Cathavina Bain CPA | CFO & Treasurer |
| Dr. Sriram Sathyanarayanan Ph.D. | Chief Scientific Officer |
| Dr. Konstantin Konstantinov Ph.D. | Chief Technology Officer |
| Mr. Christopher J. M. Taylor | VP of Investor Relations & Corp. Communications |
| Ms. Yalonda Howze | Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec. |
| Ms. Nicole Barna | Sr. VP of HR |
| Dr. David J. Mauro M.D., Ph.D. | Chief Medical Officer |
| Dr. Benny Sorensen M.D., Ph.D. | Member of Scientific Advisory Board & Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5483 |
| Price-to-Sales TTM: | 0.5943 |
| IPO Date: | 2020-10-14 |
| Fiscal Year End: | December |
| Full Time Employees: | 102 |